Treatment involves adult patients with relapsed or refractory diffuse large B-cell lymphoma
Gilead Sciences has announced that the National Institute for Health and Care Excellence (NICE) has recommended Yescarta (axicabtagene ciloleucel) for routine commissioning on the NHS across England.
Suite 11a, Cedar Court
Grove Park
White Waltham
Maidenhead
SL6 3LW
info@icr-global.org